Chirurgická liečba nádorov spojenia pažeráka

Zdieľať tento príspevok

Key points for diagnosis and treatment of tumors at the junction of gastroesophagus

1 Gastroesophageal junction (GEJ) adenocarcinoma occurs at the junction of the esophagus and stomach.

2 Accurate preoperative staging is the key to surgical decision: gastroscopy, CT and ultrasound endoscopy.

3 According to the anatomical location, GEJ tumors can be divided into three subtypes: distal esophageal cancer (type I), cardia cancer (type II) or subcardia cancer (type III).

4 According to this classification, the diagnostic accuracy of the tumor location is about 70%.

5 The seventh edition of the TNM Fenqi system recommends that GEJ tumors be divided into esophageal or gastric tumors according to the central location and extent of tumor occurrence.

Surgical

These include total esophagectomy, total gastrectomy, and esophagectomy.

The ultimate goal of surgery

1 Radical resection (R0).

2 Adequate range of lymph node dissection.

3 Cure or prolong overall survival.

4 The lowest complication rate and mortality rate.

5 Provide the best postoperative quality of life (QoL)

Intestinal adenocarcinoma VS cardia mucosa-associated adenocarcinoma

There are two different ways of tumorigenesis: the intestinal type route originates from intestinal metaplasia (Barrett’s esophagus) (Siewert type I), and the non-intestinal type route originates from cardia mucosal tissue (Siewert type II / III).

The expression of nuclear β-catenin and EGFR are significantly different.

How to determine the source of cardiac adenocarcinoma?

Tumor histology, gastric mucosa histology and gastroesophageal reflux history are the three main factors that determine the origin of GEJ adenocarcinoma from the esophagus or stomach.

The key issues of GEJ tumor surgery

Accurate preoperative staging?

The choice of surgical method?

Lymph node dissection range?

What is the source of surgery?

The mode of comprehensive treatment?

Difference in quality of life?

Oncology outcome?

Positive circumcision margin (CRM) is more common in patients who have undergone gastrectomy for Siewert type II GEJ adenocarcinoma.

Esophagectomy can get a more complete paraesophageal lymph node dissection.

The high rate of mediastinal lymph node metastasis suggests that for Siewert type II GEJ tumors, lymph node dissection in this area should be considered.

The choice of surgery and prognosis

For patients with Siewert I, II, and III type GEJ adenocarcinoma who underwent R0 resection and at least 15 lymph nodes, the margin from the proximal esophagus is greater than 3.8 cm (refers to the measurement length in vitro, the margin in the body should be greater than 5 cm) and good The prognosis is related.

Surgical goal of GEJ adenocarcinoma: to achieve R0 resection and clean up no less than 15 lymph nodes. For example, the proximal esophageal resection margin is larger than 5 cm.

Siewert type I: According to the operator’s preference, choose transthoracic esophageal cancer resection (TTE) or transseptal esophageal cancer resection (THE).

Siewert II or III: The surgical method should be selected according to the individual patient.

Scope of comprehensive treatment

For patients with esophageal cancer that is locally resectable and can tolerate surgery, it is recommended that three treatments be used in combination, namely neoadjuvant chemoradiation plus surgery.

The combination of the two treatment methods, radical radiotherapy and chemotherapy is suitable for: cervical esophageal cancer, tumors that can not be removed by surgery, the patient can not tolerate surgery because of physical conditions, and the patient refuses to operate.

Prihlásiť sa k odberu noviniek

Získajte aktualizácie a nikdy nezmeškáte blog od spoločnosti Cancerfax

Viac na preskúmanie

Úloha zdravotníkov v úspechu CAR T bunkovej terapie
Liečba T-bunkami CAR

Úloha zdravotníkov v úspechu CAR T bunkovej terapie

Záchranári zohrávajú kľúčovú úlohu v úspechu terapie CAR T-bunkami tým, že zabezpečujú bezproblémovú starostlivosť o pacienta počas celého liečebného procesu. Poskytujú životne dôležitú podporu počas prepravy, monitorujú vitálne funkcie pacientov a poskytujú núdzové lekárske zásahy v prípade komplikácií. Ich rýchla reakcia a odborná starostlivosť prispievajú k celkovej bezpečnosti a účinnosti terapie, uľahčujú plynulejšie prechody medzi zdravotníckymi zariadeniami a zlepšujú výsledky pacientov v náročnom prostredí pokročilých bunkových terapií.

Potrebujete pomoc? Náš tím je pripravený pomôcť vám.

Prajeme skoré uzdravenie vášho drahého a blízkeho človeka.

Spustiť chat
Sme online! Chatujte s nami!
Naskenujte kód
Ahoj,

Vitajte v CancerFax!

CancerFax je priekopnícka platforma venovaná spájaniu jednotlivcov, ktorí čelia pokročilému štádiu rakoviny, pomocou prelomových bunkových terapií, ako sú CAR T-Cell terapia, TIL terapia a klinické štúdie na celom svete.

Dajte nám vedieť, čo pre vás môžeme urobiť.

1) Liečba rakoviny v zahraničí?
2) CAR T-bunková terapia
3) Vakcína proti rakovine
4) Online video konzultácia
5) Protónová terapia